Lexeo Therapeutics, Inc. short interest in 2024
In 2024, Lexeo Therapeutics, Inc.'s disclosed short interest ran from 0.69% of shares outstanding on 12 Jan 2024 to 6.77% on 31 Dec 2024, a change of +6.08 percentage points. The year's high was 7.54% on 15 Nov 2024 and its low 0.69% on 12 Jan 2024, averaging 3.90% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.94 days on 31 Dec 2024. Full history: Lexeo Therapeutics, Inc..
Cite this page
2024 in figures
- Start of year
- 0.69% (12 Jan 2024)
- End of year
- 6.77% (31 Dec 2024)
- Change
- +6.08 pp
- High
- 7.54% (15 Nov 2024)
- Low
- 0.69% (12 Jan 2024)
- Average
- 3.90%
- Highest days to cover
- 11.94 (31 Dec 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.69% | 2.77 | |
| 31 Jan 2024 | 1.13% | 2.63 | |
| 15 Feb 2024 | 1.32% | 6.53 | |
| 29 Feb 2024 | 1.27% | 4.65 | |
| 15 Mar 2024 | 1.80% | 2.13 | 10-K filed, results (8-K) |
| 28 Mar 2024 | 2.94% | 9.32 | |
| 15 Apr 2024 | 3.14% | 10.67 | |
| 30 Apr 2024 | 2.61% | 5.18 | |
| 15 May 2024 | 2.57% | 5.85 | 10-Q filed, results (8-K) |
| 31 May 2024 | 2.04% | 3.66 | |
| 14 Jun 2024 | 2.36% | 2.77 | |
| 28 Jun 2024 | 2.91% | 3.40 | |
| 15 Jul 2024 | 3.15% | 1.45 | |
| 31 Jul 2024 | 6.23% | 4.25 | |
| 15 Aug 2024 | 5.85% | 7.89 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 3.76% | 8.07 | |
| 13 Sep 2024 | 3.61% | 6.54 | |
| 30 Sep 2024 | 6.27% | 4.13 | |
| 15 Oct 2024 | 6.23% | 8.47 | |
| 31 Oct 2024 | 6.64% | 5.49 | |
| 15 Nov 2024 | 7.54% | 3.00 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 6.66% | 9.75 | |
| 13 Dec 2024 | 6.20% | 6.26 | |
| 31 Dec 2024 | 6.77% | 11.94 |
See also: Lexeo Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.